ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Shionogi files for COVID oral drug approval after delay in trials

Osaka-based company is the first to develop treatment pill in Japan

Shionogi aims to make the drug available to the public this year. (Source photos by Jiji and courtesy of Shionogi)

TOKYO -- Japanese drugmaker Shionogi on Friday filed for emergency use approval for its COVID pill, paving the way for Japan's first domestically developed oral COVID treatment.

The drug, code-named S-217622, prevents the coronavirus from replicating in infected cells by inhibiting its protease, an enzyme for protein production. The drug has been in the clinical trial stage since July.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more